Keywords: allergic, reactions, halozyme, rhuph20, drugmaker, therapeutics, reported
No allergic reactions from Halozyme's rHuPH20
Article | 04 July 2005
US drugmaker Halozyme Therapeutics has reported results from a clinical trial demonstrating the absence of allergic reactions to its recombinant ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
